Published in

Springer Nature [academic journals on nature.com], Molecular Psychiatry, 3(13), p. 261-266, 2007

DOI: 10.1038/sj.mp.4002049

Springer Nature [academic journals on nature.com], Molecular Psychiatry, 11(15), p. 1121-1121, 2010

DOI: 10.1038/mp.2010.20

Links

Tools

Export citation

Search in Google Scholar

CNTNAP2 gene dosage variation is associated with schizophrenia and epilepsy.

This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

A homozygous mutation of the CNTNAP2 gene has been associated with a syndrome of focal epilepsy, mental retardation, language regression and other neuropsychiatric problems in children of the Old Order Amish community. Here we report genomic rearrangements resulting in haploinsufficiency of the CNTNAP2 gene in association with epilepsy and schizophrenia. Genomic deletions of varying sizes affecting the CNTNAP2 gene were identified in three non-related Caucasian patients. In contrast, we did not observe any dosage variation for this gene in 512 healthy controls. Moreover, this genomic region has not been identified as showing large-scale copy number variation. Our data thus confirm an association of CNTNAP2 to epilepsy outside the Old Order Amish population and suggest that dosage alteration of this gene may lead to a complex phenotype of schizophrenia, epilepsy and cognitive impairment.